Islay Capital Management LLC Makes New $93,000 Investment in Moderna, Inc. (NASDAQ:MRNA)

Islay Capital Management LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 365 shares of the company’s stock, valued at approximately $93,000.

A number of other hedge funds also recently made changes to their positions in MRNA. Glassman Wealth Services raised its holdings in shares of Moderna by 13.6% in the third quarter. Glassman Wealth Services now owns 360 shares of the company’s stock valued at $139,000 after purchasing an additional 43 shares during the last quarter. Jacobi Capital Management LLC boosted its holdings in Moderna by 9.9% during the third quarter. Jacobi Capital Management LLC now owns 501 shares of the company’s stock worth $193,000 after purchasing an additional 45 shares during the last quarter. D Orazio & Associates Inc. grew its position in Moderna by 15.7% in the third quarter. D Orazio & Associates Inc. now owns 347 shares of the company’s stock valued at $134,000 after purchasing an additional 47 shares in the last quarter. RB Capital Management LLC increased its stake in Moderna by 2.5% in the 3rd quarter. RB Capital Management LLC now owns 1,965 shares of the company’s stock valued at $756,000 after buying an additional 47 shares during the last quarter. Finally, AFT Forsyth & Company Inc. lifted its position in Moderna by 1.0% during the 3rd quarter. AFT Forsyth & Company Inc. now owns 5,060 shares of the company’s stock worth $1,947,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 60.11% of the company’s stock.

A number of analysts recently issued reports on MRNA shares. Redburn Partners raised Moderna from a “sell” rating to a “neutral” rating in a research report on Tuesday, February 1st. TheStreet downgraded Moderna from a “b-” rating to a “c+” rating in a research report on Thursday, February 24th. Jefferies Financial Group lowered their target price on Moderna from $200.00 to $170.00 in a research report on Friday, February 25th. Morgan Stanley lifted their target price on Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. Finally, SVB Leerink lowered their target price on Moderna from $81.00 to $80.00 and set an “underperform” rating on the stock in a research report on Friday, March 25th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $242.71.

Moderna stock traded up $4.77 during midday trading on Monday, reaching $145.11. 98,444 shares of the company’s stock were exchanged, compared to its average volume of 7,809,160. Moderna, Inc. has a 52 week low of $122.01 and a 52 week high of $497.49. The firm has a market cap of $58.48 billion, a price-to-earnings ratio of 4.96, a P/E/G ratio of 0.82 and a beta of 1.55. The stock’s 50-day simple moving average is $157.26 and its 200 day simple moving average is $219.30. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.60 and a current ratio of 1.76.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The company reported $11.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.83 by $1.46. Moderna had a return on equity of 140.21% and a net margin of 66.06%. The company had revenue of $7.21 billion during the quarter, compared to analysts’ expectations of $6.73 billion. During the same quarter in the previous year, the company posted ($0.69) earnings per share. The business’s revenue was up 1163.3% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post 26.97 earnings per share for the current year.

In other news, CFO David W. Meline sold 619 shares of Moderna stock in a transaction that occurred on Thursday, February 10th. The shares were sold at an average price of $158.89, for a total value of $98,352.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Stephen Hoge sold 10,000 shares of Moderna stock in a transaction that occurred on Wednesday, February 2nd. The shares were sold at an average price of $170.89, for a total transaction of $1,708,900.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 188,054 shares of company stock valued at $30,802,414. Corporate insiders own 17.30% of the company’s stock.

Moderna Company Profile (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.